모제나비르

Mozenavir
모제나비르
Mozenavir.svg
임상자료
상명모제나비르
법적현황
법적현황
식별자
  • (4R,5S,6S,7R)-1,3-bis[(3-아미노페닐)메틸]-4,7-디벤질-5,6-디하이드록시-1,3-디아제판-2-1
CAS 번호
펍켐 CID
켐스파이더
유니
CompTox 대시보드 (EPA)
화학 및 물리적 데이터
공식C33H36N4O3
어금질량536.7 g·190−1
3D 모델(JSmol)
  • C1=CC=C(C=C1)C[C@H]2[C@H]([C@H]([C@H])(N(=O)N2CC3=CC(=CC=C3)N)CC4=CC(=CC=C4)N)CC5=CC=CC=C5)O)o
  • InChI=1S/C33H36N4O3/c34-27-15-7-13-25(17-27)21-36-29(19-23-9-3-1-4-10-23)31(38)32(39)30(20-24-11-5-2-6-12-24)37(33(36)40)22-26-14-8-16-28(35)18-26/h1-18,29-32,38-39H,19-22,34-35H2/t29-,30-,31+,32+/m1/s1
  • 키:KYRSNWPSSNEP-ZRTHHSRSRSSA-N

모제나비르(DMP-450)는 에이즈 치료제로 개발된 항바이러스제.그것은 HIV 단백질 분해효소 억제제 역할을 하며 높은 친화력으로 이 대상에 결합하지만,[1][2] 초기 실험에서 유망한 결과에도 불구하고,[3][4] 모제나비르는 인간 임상 실험에서 성공하지 못했다.관련 파생상품에 대한 연구가 계속되고 있다.[5]

참조

  1. ^ Nugiel DA, Jacobs K, Kaltenbach RF, Worley T, Patel M, Meyer DT, et al. (May 1996). "Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors". Journal of Medicinal Chemistry. 39 (11): 2156–69. doi:10.1021/jm960083n. PMID 8667359.
  2. ^ Patel M, Bacheler LT, Rayner MM, Cordova BC, Klabe RM, Erickson-Viitanen S, Seitz SP (April 1998). "The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues". Bioorganic & Medicinal Chemistry Letters. 8 (7): 823–8. doi:10.1016/s0960-894x(98)00119-x. PMID 9871548.
  3. ^ De Clercq E (April 2002). "Highlights in the development of new antiviral agents". Mini Reviews in Medicinal Chemistry. 2 (2): 163–75. doi:10.2174/1389557024605474. PMID 12370077.
  4. ^ Hensen C, Hermann JC, Nam K, Ma S, Gao J, Höltje HD (December 2004). "A combined QM/MM approach to protein--ligand interactions: polarization effects of the HIV-1 protease on selected high affinity inhibitors". Journal of Medicinal Chemistry. 47 (27): 6673–80. doi:10.1021/jm0497343. PMID 15615516.
  5. ^ Li P, Wang S, Wang H, Yan H (2019). "2-Symmetric HIV-1 Protease Inhibitors and Docking Study". Biological & Pharmaceutical Bulletin. 42 (2): 261–267. doi:10.1248/bpb.b18-00705. PMID 30713256.